Native Tobacco Plants as Sustainable ‘Biofactories' for Oral MedicinesJune 7, 2023
Researchers at Australia's University of Queensland (UQ) reveal that Australian tobacco plants could be used as ‘biofactories' for large-scale manufacturing of medicines. Professor David Craik and Dr. Mark Jackson from UQ's Institute for Molecular Bioscience showed that native wild tobacco, Nicotiana benthamiana, can potentially produce large quantities of drugs in a cheaper and more sustainable method.
According to Professor Craik, they will use the natural ability of plants to produce cyclotides, the strings of amino acids in a circular shape, making them stable and suitable as oral drugs. The research team will use modern molecular biology techniques to effectively instruct the plant cell to produce the molecule of interest. The research team grew the drug T20K, which is currently in phase 1 clinical trials to treat multiple sclerosis, a devastating autoimmune disease affecting the central nervous system. Professor Craik said T20K is the first cyclotide drug to reach clinical trials, and he is hopeful that more will follow and reach the market.
“Harnessing plants as ‘biofactories' is more cost-effective as it uses fewer resources and is less wasteful, with a much simpler production process,” Dr. Jackson said.
For more details, read the article in UQ News.
You might also like:
- Native Australian Plant Paves Way for Vaccine Development Against COVID-19
- Researchers Use NBTs to Develop Tobacco Plants as Biofactories
- Brightest Engineered Plants Glow Throughout Life Cycle
Biotech Updates is a weekly newsletter of ISAAA, a not-for-profit organization. It is distributed for free to over 22,000 subscribers worldwide to inform them about the key developments in biosciences, especially in biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
- Case Studies Reveal Keys to Sustainable Seed Access in Eastern Africa
- Italy Approves Field Trial of NBT Products
- EFSA: Six-Event Stack Maize and 30 Subcombinations as Safe as Non-GM Maize
- ISAAA Inc. to Hold ASCA6 on September 11-15 in Indonesia
- CRISPR-Cas9 Reveals a Gene Necessary in Coral Skeleton Formation
- Animal Biotechnology Symposium and Stakeholder Consultation on the Proposed Guidelines for GM Animals and Animal Products in the Philippines
- Experts Say Effective Communication Can Promote Consumer Acceptance of Cultured Meat
- Native Tobacco Plants as Sustainable ‘Biofactories' for Oral Medicines
- US EPA Releases Final Rule on Regulating Gene-edited Crops
Read the latest:
- Biotech Updates (September 27, 2023)
- Gene Editing Supplement (September 27, 2023)
- Gene Drive Supplement (February 22, 2023)
Subscribe to BU: